Received: 12 August 2020
Accepted: 3 March 2021
First Online: 22 March 2021
: Institutional review board approval was obtained prior to initiating the study (approval number: 2018–1013). All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Specific informed consent for this retrospective and non-invasive study was not required by local ethics committee.
: Not applicable since there are no details on individuals reported within the manuscript.
: SH reports personal fees from BD, Meiji, Shionogi, Sumitomo Dainippon Pharma, MSD, Astellas, Beckman Coulter Diagnostics, and FUJIFILM Toyama Chemical, and grants from MSD, outside the submitted work. YD reports personal fees from Pfizer, MSD, Shionogi, Janssen, VenatoRx, Entasis, BD, bioMerieux, Gilead, and AstraZeneca, and grants from Pfizer, MSD, Astellas, Shionogi, Kanto Chemical, and Janssen, outside the submitted work. All other authors declare no conflict of interest relevant to the study.